SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following the announcement of a $1.4 billion debt exchange that converts convertible senior notes into common stock, sparking intense community debate over long-term balance sheet benefits versus immediate shareholder dilution. Investors remain sharply divided, with bulls viewing the move as a strategic cleanup of debt to facilitate future acquisitions, while bears and frustrated shareholders are criticizing management for the impact on equity value.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is capturing significant attention as investors await the upcoming earnings report, with community discourse heavily polarized between long-term bullish conviction in its enterprise AI adoption and skepticism regarding its high valuation and recent stock price volatility. Market participants are intensely focused on the company's ability to maintain its rapid growth trajectory in commercial revenue and provide strong forward guidance to justify its premium multiple.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending as traders debate the stock's future ahead of earnings, with speculation focused on the potential for a massive short squeeze, buyout rumors, and the upcoming launch of their new AR glasses. Community members are divided, with some betting on a speculative re-rating while others remain deeply frustrated by management's control structure and persistent share price weakness.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is seeing a massive, broad-based rally as market participants react to geopolitical headlines and Trump's comments regarding potential negotiations, fueling a surge that is squeezing out short sellers. While bulls are celebrating the rapid V-shaped recovery toward all-time highs, the community remains deeply divided, with many traders questioning the legitimacy of the move due to perceived low volume and market manipulation.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending due to a 10-3 favorable vote from the FDA advisory committee regarding the efficacy of RP1 in advanced melanoma, sparking intense speculation about a potential reversal of the company's previous regulatory setbacks. The community is sharply divided, with longs anticipating a massive short squeeze and potential buyout, while skeptics warn that the "messy" data and unresolved deficiencies from prior rejections make an approval or a clean commercial launch highly improbable.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is currently trending as investors debate the impact of strong Briumvi sales versus higher operating costs following a recent earnings report. The community remains highly bullish on the company's long-term pipeline, widely discussing the potential for a major buyout while dismissing current price volatility as orchestrated short-selling.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is experiencing heightened investor interest amid the unfolding Middle East conflict, with community discussions largely centered on the impact of ongoing geopolitical disruptions on global oil supply and refining margins. While some investors remain bullish on the energy sector due to these supply constraints, others are closely tracking the company's long-term energy transition strategy, particularly its recent push into natural gas-powered data center infrastructure for AI.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors show heightened anticipation for the imminent release of phase 3 IZAR-1 trial results. Community sentiment remains deeply divided, with many shareholders frustrated by recent price volatility and delays in data, while others view the current valuation as a strategic entry point ahead of potential clinical catalysts.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors monitor volatile price swings and institutional activity following a major portfolio transition to Citadel. The community remains heavily focused on the stock's role in the AI infrastructure space, with active debates centered on whether recent price action represents a sustainable recovery or a speculative trap leading into upcoming earnings.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending as investors rally around the company's strong earnings momentum, record-breaking loan volume, and improved profitability metrics. Community discussion is heavily focused on the stock's perceived undervaluation relative to peers, with many participants highlighting institutional accumulation and the anticipation of further analyst price target upgrades.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised

Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.

Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates

Amneal (AMRX) delivered earnings and revenue surprises of +25.00% and +3.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals, Inc. Q2 Profit Advances

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) released earnings for its second quarter that Increases, from last year...

Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm

Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (Amneal) on behalf of the companys current shareholders. The investigation seeks to determine whether Amneal or the companys officers and/or directors violated the securities laws or breached their fiduciary duties in...

Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?

Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$0.23	--	--	N/A
Q2 '26	$0.22	$0.30	34.81%	BEAT
Q1 '26	$0.17	$0.27	59.64%	BEAT
Q4 '25	$0.18	$0.21	14.07%	BEAT
Q3 '25	$0.14	$0.17	22.88%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings